North China Pharmaceutical Company.Ltd (SHSE:600812) agreed to acquire the remaining 35.85% stake in NCPC Hebei Huamin Pharmaceutical Co., Ltd. from CCB Financial Asset Investment Co., Ltd. for CNY 670 million on March 28, 2024. The definitive agreement is expected to be signed before April 3, 2024, and the transaction is expected to close by April 12, 2024. NCPC Hebei Huamin Pharmaceutical reported total assets of CNY 2.4 billion and net assets of CNY 1.2 billion for the period ended February 29, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5.14 CNY | +4.68% | +13.47% | -9.82% |
1st Jan change | Capi. | |
---|---|---|
-9.82% | 1.16B | |
+26.47% | 661B | |
+26.74% | 566B | |
-6.33% | 352B | |
+19.35% | 332B | |
+4.23% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.04% | 145B |
- Stock Market
- Equities
- 600812 Stock
- News North China Pharmaceutical Company.Ltd
- North China Pharmaceutical Company.Ltd agreed to acquire the remaining 35.85% stake in NCPC Hebei Huamin Pharmaceutical Co., Ltd. from CCB Financial Asset Investment Co., Ltd. for CNY 670 million